Medicenna Therapeutics Corp. - Special Call Transcript
Good day, ladies and gentlemen, and welcome, everyone, to Medicenna's Analyst Call focused on MDNA19 and the nonhuman primate results for its IL-2 Superkine program. (Operator Instructions) And as a reminder, today's conference call is being recorded.
Before we begin, I would like to remind you that except for historical information, this presentation contains forward-looking statements, which reflects Medicenna's current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Medicenna's actual results to differ materially from those statements.
Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly and annual information form available on the company's website.
This forward-looking statement is also based on a number of assumptions, which may prove to be incorrect. Forward-looking statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |